Areteia Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Areteia Therapeutics, Inc. - overview
Established
2022
Location
Chapel Hill, NC, US
Primary Industry
Biotechnology
About
Based in North Carolina, US, Areteia Therapeutics, Inc. was created by Population Health Partners and Knopp Biosciences in 2022 and is a biopharmaceutical company in its clinical stage that develops an oral drug for eosinophilic asthma. In February 2024, Areteia Therapeutics, Inc. raised USD 75 million in series A funding led by returning investor Bain Capital Life Sciences, with participation from new investors Viking Global Investors and Marshall Wace.
Returning investors Access Industries, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners also participated in the round. The round was part of a larger USD 425 million series A funding. The company is conducting clinical trials of its oral medicine dexpramipexole, which has the potential to target eosinophils in the blood and prevent them from traveling through the blood to the lungs of people suffering from eosinophilic asthma and reducing their effect on the lungs before they cause further damage. The company intends to use the July 2022 funding to promote its advanced dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines.
Current Investors
ARCH Venture Partners, Access Industries, GV
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.areteiatx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.